{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T01:58:07Z","timestamp":1715479087892},"reference-count":22,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3960\/jslrt.54.171","type":"journal-article","created":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T23:18:21Z","timestamp":1418599101000},"page":"171-177","source":"Crossref","is-referenced-by-count":5,"title":["The Association of nm23-H1 Expression with a Poor Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"prefix":"10.3960","volume":"54","author":[{"given":"Nozomi","family":"Niitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Vose J1, Armitage J, Weisenburger D: International T-Cell Lymphoma Project: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2","unstructured":"2 WHO Classification of Tumours, Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, <i>et al<\/i>. (eds): 4th ed, Lyon, IARC, 2008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 A predictive model for aggressive non-Hodgkin&apos;s lymphoma. The International Non-Hodgkin&apos;s Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993","DOI":"10.1056\/NEJM199309303291402"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, <i>et al<\/i>.: Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin&apos;s lymphoma. Blood 94:3541-3550, 1999","DOI":"10.1182\/blood.V94.10.3541.422k15_3541_3550"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, <i>et al<\/i>.: Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin&apos;s lymphoma. Blood 97:1202-1210, 2001","DOI":"10.1182\/blood.V97.5.1202"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Niitsu N, Nakamine H, Okamoto M, Akamatsu H, Higashihara M, <i>et al<\/i>.: Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res 10:2482-2490, 2004","DOI":"10.1158\/1078-0432.CCR-03-0085"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, <i>et al<\/i>.: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200-204, 1988","DOI":"10.1093\/jnci\/80.3.200"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 MacDonald NJ, de La Rosa A, Steeg PS: The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 31A:1096-1100, 1995","DOI":"10.1016\/0959-8049(95)00152-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Steeg PS, Horak CE, Miller KD: Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 14:5006-5012, 2008","DOI":"10.1158\/1078-0432.CCR-08-0238"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Marino N, Nakayama J, Collins JW, Steeg PS: Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene. Cancer Metastasis Rev 31:593-603, 2012","DOI":"10.1007\/s10555-012-9374-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Zhu J, Tseng YH, Kantor JD, Rhodes CJ, Zetter BR, <i>et al<\/i>.: Interaction of the Ras-related protein associated with diabetes rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation. Proc Natl Acad Sci U S A 96:14911-14918, 1999","DOI":"10.1073\/pnas.96.26.14911"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Paravicini G, Steinmayr M, Andr\u00e9 E, Becker-Andr\u00e9 M. The metastasis suppressor candidate nucleotide diphosphate kinase NM23 specifically interacts with members of the ROR\/RZR nuclear orphan receptor subfamily. Biochem Biophys Res Commun 227:82-87, 1996","DOI":"10.1006\/bbrc.1996.1471"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Okabe-Kado J, Kasukabe T: Physiological and pathological relevance of extracellular NM23\/NDP kinases. J Bioenerg Biomembr 35:89-93, 2003","DOI":"10.1023\/A:1023402125186"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Niitsu N, Nakamine H, Okamoto M: Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specified. Clin Cancer Res 17:2893-2899, 2011","DOI":"10.1158\/1078-0432.CCR-10-2999"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, <i>et al<\/i>.: Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 26:152-158, 2008","DOI":"10.1002\/hon.853"},{"key":"17","unstructured":"17 Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, <i>et al<\/i>.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004"},{"key":"18","unstructured":"18 Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, <i>et al<\/i>.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1trial of the DSHNHL. Blood 104:626-633, 2004"},{"key":"19","unstructured":"19 Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, <i>et al<\/i>.: High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20:1977-1984, 2009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, <i>et al<\/i>.: Groupe d&apos;Etude des Lymphomes de l&apos;Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003","DOI":"10.1182\/blood-2003-02-0542"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Niitsu N, Hayama M, Yoshino T, Nakamura S, Tamaru J, <i>et al<\/i>.: Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol 153:582-588, 2011","DOI":"10.1111\/j.1365-2141.2011.08634.x"},{"key":"22","unstructured":"22 Okabe-Kado J, Kasukabe T, Kaneko Y: Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies. Adv Hematol"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:46Z","timestamp":1621540006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/54\/3\/54_171\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.54.171","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}